Danaher recently reported a 4 percent year-over-year increase in its third quarter revenues, which included a 6 percent rise in life sciences segment revenues and an increase in its diagnostics segment of almost 7 percent.

Qiagen reported after the close of the market recently that its third quarter revenues increased 1 percent year over year, missing analysts' consensus estimate.

Beckman Coulter Life Sciences and IncellDx said recently that they have partnered to promote in Europe four newly developed cancer assays that incorporate technology from each company.

Roche said recently it has commenced a tender offer to purchase for cash a combined aggregate purchase price of up to $2 billion of certain notes.

Epigenetics research and sample preparation service provider Diagenode announced recently that it has partnered with Bio-Rad Laboratories to offer its single-cell transposase accessible chromatin by sequencing (ATAC-seq) services on...

Qiagen said recently that it has received several "conditional, non-binding indications of interest" from potential merger or acquisition partners.

Becton Dickinson is advising its shareholders to reject an unsolicited mini-tender offer they may have received to sell their shares of the company's stock.

Becton Dickinson said on Tuesday that it has submitted a premarket approval (PMA) supplement to the US Food and Drug Administration for an expanded version of its Onclarity human papilloma virus (HPV) assay.

Australian molecular diagnostics firm Genetic Signatures has raised $25 million, it said recently.

A consortium led by private equity firms Cinven and Astorg said recently that it has signed an agreement to acquire life science tools company LGC for an undisclosed amount, subject to regulatory approval and other customary clearances.

British life science reagents and tools company Abcam said recently that it has signed an agreement to use BrickBio's proprietary bioconjugation platform to develop research and diagnostic products.

Invitae said recently that it will acquire Clear Genetics, a developer of software that supports the delivery of genetics services at scale, for approximately $50 million.

Expedeon announced recently that it has agreed to sell its immunology and proteomics businesses to UK-based life science reagents and tools company Abcam for €120 million ($130.0 million) in cash.

Castle Biosciences reported after the close of the market recently that its third quarter revenues skyrocketed 300 percent year over year due to growth in the firm's DecisionDx- Melanoma test report volume.

Liquid biopsy firm Lexent Bio recently announced a non-exclusive partnership with Illumina to develop an in vitro diagnostic kit for cancer.